Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other financing activities (2019 - 2025)

Historic Other financing activities for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $419000.0.

  • Kymera Therapeutics' Other financing activities fell 3463.34% to $419000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 28296.09%. This contributed to the annual value of $1.6 million for FY2024, which is 197368.42% up from last year.
  • As of Q3 2025, Kymera Therapeutics' Other financing activities stood at $419000.0, which was down 3463.34% from $382000.0 recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Other financing activities registered a high of $641000.0 during Q3 2024, and its lowest value of -$925000.0 during Q4 2023.
  • In the last 5 years, Kymera Therapeutics' Other financing activities had a median value of $293000.0 in 2024 and averaged $247842.1.
  • Its Other financing activities has fluctuated over the past 5 years, first surged by 22293.58% in 2021, then crashed by 40327.87% in 2023.
  • Kymera Therapeutics' Other financing activities (Quarter) stood at $156000.0 in 2021, then soared by 95.51% to $305000.0 in 2022, then plummeted by 403.28% to -$925000.0 in 2023, then skyrocketed by 131.68% to $293000.0 in 2024, then skyrocketed by 43.0% to $419000.0 in 2025.
  • Its last three reported values are $419000.0 in Q3 2025, $382000.0 for Q2 2025, and $277000.0 during Q1 2025.